Microneedle-delivered biomimetic nanodecoys target type Ⅳ collagen and scavenge multiple cytokines to alleviate psoriatic inflammation  

作　　者：Fei Qu Jinying Qin Min Li Yuting Xia Yihui Wang Hongmei Liu Juan Tao Yijing Liu Jintao Zhu 

机构地区：[1]Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica,Hubei Engineering Research Center for Biomaterials and Medical Protective Materials,School of Chemistry and Chemical Engineering,Huazhong University of Science and Technology,Wuhan 430074,China [2]Department of Dermatology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China [3]Department of Ultrasound Medicine,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China [4]Shenzhen Huazhong University of Science and Technology Research Institute,Shenzhen 518057,China

出　　处：《Nano Research》2025年第3期401-416,共16页纳米研究(英文版)

基　　金：financially supported by the National Natural Science Foundation of China(No.52373138);the Fundamental Research Funds for the Central Universities(HUST:2023JYCXJJ052 and 2020kfyXJJS060);Shenzhen Science and Technology Program(No.CYJ20220530160603007).

摘　　要：The immunomodulatory efficacy of current psoriasis biological therapies is hindered by their limited ability to scavenge multiple cytokines,inefficient delivery to specific inflamed skin regions,and potential side effects.Upon analyzing samples from both patients and mice,we identify a significant increase in type Ⅳ collagen within the extracellular matrix(ECM)of psoriatic skin.Thus,we report the microneedle(MN)delivery of type Ⅳ collagen targeting peptide-modified dual-cell membrane biomimetic nanodecoys(CRHM@lip)with multiple cytokines scavenging ability for treating psoriasis.The CRHM@lip can scavenge both tumor necrosis factor-α(TNF-α)and interleukin(IL)-17.Upon MN delivery,the nanodecoys target ECM and exhibit skin retention for over 120 h.The treatment by CRHM@lip-integrated MNs reduces skin thickness in mice by 57.9%and shows decreased levels of TNF-α,IL-17,IL-23,and interferon(IFN)-γ in skin sections compared to the psoriasis group.Additionally,the CRHM@lip treatment reduces the CD4^(+)T cells,M1 macrophages,and dendritic cells in the spleen,and suppresses various inflammatory mediators in serum,significantly demonstrating immunological microenvironmental suppression.Compared to systemic administration routes,MN delivery improves treatment outcomes.No noticeable adverse effects on hepatic and renal functions are observed in mice after treatment.This approach enhances the effectiveness of biological therapies and has the potential for translation.

关 键 词：nanodecoy MICRONEEDLE type IV collagen-targeting cytokines scavenging PSORIASIS 

分 类 号：R73[医药卫生—肿瘤]